在动脉样硬化细胞生理学中MEG3的作用
Yu-Ting Wu1, Zhi-Jun Guo1, Jiang-Bin Li2
1Department of Geriatrics, Quanzhou First Hospital, Quanzhou, Fujian, China.
Annals of clinical and laboratory science
|August 25, 2023
概括
长非编码RNA MEG3 (MEG3) 在动脉样硬化 (AS) 中是下调的. 过度表达MEG3会降低脂质积累并增强胆固醇排放,这表明它通过miR-200b-3p/ABCA1通路作为抗动脉样硬化因子.
科学领域:
- 分子生物学分子生物学
- 心血管研究研究心血管研究
- 遗传学 是一个遗传学.
背景情况:
- 动脉样硬化 (AS) 涉及复杂的生化过程.
- 长非编码RNAs (lncRNAs) 越来越多地被认为是它们在疾病发病过程中的角色.
研究的目的:
- 研究lncRNA MEG3在抵消动脉样硬化发展背后的生化机制中的作用.
- 阐明AS中涉及MEG3,miR-200b-3p和ABCA1的分子途径.
主要方法:
- 在AS患者和使用RT-qPCR的健康对照中分析MEG3,miR-200b-3p和ABCA1的表达.
- 在巨细胞衍生的泡细胞中评估脂质积累和胆固醇流出.
- 双 luciferase 试验用于确定 MEG3,miR-200b-3p 和 ABCA1.1.p 之间的向关系.
主要成果:
- 在AS患者中,MEG3和ABCA1的表达减少,而miR-200b-3p则上调.
- 在泡细胞中MEG3的过度表达减少了脂质积累,增加了胆固醇排泄.
- 过度表达MEG3导致miR-200b-3p减少和ABCA1表达增加,由共同表达的miR-200b-3p部分逆转.
结论:
- 在动脉样硬化和泡细胞中,MEG3的表达减少.
- 上调的MEG3通过调节脂质积累和胆固醇流量来表现出抗动脉样硬化作用.
- 在AS中,miR-200b-3p/ABCA1轴是MEG3保护功能的关键调解者.
相关概念视频
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:30Atherosclerosis I: Introduction
10
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
10
01:38Inflammation
53.8K
Overview
53.8K
01:26Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:30Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20